中国P站

Dysbiosis; Gut microbiota; Immune dysregulation; Mucosal immunity; Inflammatory diseases; Probiotics; Gut-brain axis

Introduction

The gut microbiota, a complex and diverse community of microorganisms residing in the gastrointestinal tract, is vital for maintaining immune homeostasis and modulating systemic immune responses. Under normal circumstances, the microbiota contributes to the development and regulation of the immune system, supporting the host’s ability to distinguish between harmless antigens and harmful pathogens. The gut microbiome influences mucosal immunity, particularly in the gut, where immune cells interact with microbes to promote tolerance and prevent excessive inflammation [1]. However, when the balance of microbial communities is disturbed, a condition known as dysbiosis occurs. Dysbiosis is characterized by a reduction in microbial diversity and the overgrowth of potentially pathogenic species, which disrupts normal immune function and leads to chronic inflammation. Dysbiosis has been implicated in the pathogenesis of various inflammatory conditions, including inflammatory bowel disease (IBD), autoimmune diseases, allergies, and metabolic disorders [2]. The mechanisms by which dysbiosis induces immune dysregulation are multifaceted and include alterations in microbial-derived metabolites, such as short-chain fatty acids (SCFAs), which influence immune cell function. Additionally, dysbiosis can disrupt the integrity of the gut barrier, leading to systemic inflammation. The role of the gut-brain axis in mediating the impact of dysbiosis on neuroinflammation and behavior is also an area of growing interest [3]. This review aims to explore the relationship between gut dysbiosis and immune dysregulation, focusing on how microbial imbalances contribute to inflammatory diseases. By understanding these mechanisms, new therapeutic strategies targeting the microbiota may be developed to restore immune balance and reduce inflammation in patients with chronic inflammatory diseases [4].

Methods

A comprehensive review of the literature was conducted using databases such as PubMed, Scopus, and Google Scholar to gather relevant studies. The inclusion criteria focused on studies published within the last two decades to ensure the relevance and accuracy of the findings. The studies reviewed encompassed both animal models and human clinical trials, and included research on the impact of dysbiosis on mucosal immunity, systemic inflammation, and the development of inflammatory diseases [5]. Studies examining microbial diversity, immune cell populations, gut permeability, and the production of microbial metabolites were prioritized. The methods employed in the studies reviewed included microbial profiling through 16S rRNA sequencing, cytokine analysis, immunohistochemistry, and metabolic assays. Results were synthesized to examine the mechanisms by which dysbiosis contributes to immune dysfunction and to evaluate potential therapeutic strategies, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT) [6].

Results

The review revealed significant evidence supporting the link between gut dysbiosis and immune dysregulation, leading to both local and systemic inflammation. Dysbiosis was shown to alter the composition of the gut microbiota, favoring pathogenic microbes while decreasing beneficial microorganisms that support immune tolerance. This imbalance disrupts the gut barrier integrity, allowing endotoxins and microbial metabolites to translocate into the bloodstream and trigger systemic inflammation. Dysbiosis was also associated with altered immune cell responses, including the activation of pro-inflammatory T cells and the suppression of regulatory T cells, which are critical for maintaining immune balance. Furthermore, microbial-derived metabolites, such as short-chain fatty acids (SCFAs), play a crucial role in modulating immune function. In the context of dysbiosis, reduced SCFA production has been linked to the impairment of anti-inflammatory responses. Dysbiosis has been implicated in various inflammatory conditions, including inflammatory bowel disease (IBD), rheumatoid arthritis, and metabolic syndrome. The review also highlighted that interventions aimed at restoring microbiota balance, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), have shown promise in reducing inflammation and improving immune function. These interventions help restore microbial diversity and support immune homeostasis, thus providing potential therapeutic options for managing immune-related diseases.

Discussion

The findings of this review demonstrate the critical role of gut microbiota in immune regulation and its influence on the development of inflammatory diseases. Dysbiosis, characterized by an imbalance in microbial communities, disrupts immune homeostasis by altering immune cell function, promoting inflammation, and impairing the gut barrier [6]. Microbial metabolites, particularly short-chain fatty acids (SCFAs), play a pivotal role in regulating immune responses. SCFAs have been shown to enhance the function of regulatory T cells and support the integrity of the gut epithelial barrier, both of which are crucial for maintaining tolerance and preventing inflammation. The gut-brain axis is another important pathway through which dysbiosis affects immune function, with emerging evidence linking gut microbial imbalances to neuroinflammation and behavioral disorders. Therapeutic interventions, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), have shown potential in restoring microbial balance and reducing inflammation [7]. However, while these interventions hold promise, their effectiveness in clinical settings is still under investigation, and more research is needed to determine the specific microbial species or metabolites that contribute to immune modulation. Furthermore, understanding how environmental factors, such as diet, stress, and antibiotic use, influence the microbiome will be essential for developing personalized treatment strategies for inflammatory diseases [8].

Conclusion

In conclusion, gut dysbiosis plays a central role in immune dysregulation, contributing to the pathogenesis of various inflammatory diseases. The disruption of microbial balance in the gut impairs immune tolerance, alters immune cell responses, and promotes systemic inflammation. Understanding the mechanisms through which dysbiosis induces immune dysfunction is essential for developing effective therapeutic strategies. Interventions aimed at restoring microbial balance, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), hold promise in reducing inflammation and improving immune function in patients with chronic inflammatory diseases. However, further research is needed to optimize these therapies and to explore the potential of microbiome-based interventions in clinical practice. Ultimately, a deeper understanding of the complex interactions between gut microbiota and the immune system will pave the way for new treatments to manage immune-related diseases and improve patient outcomes.

References

1. Borges GA, Tortorella G, Rossini M, Portioli SA (2019) Journal of Health Organization and Management 33: 304-322.

   , ,

2. Nabi G (2021) Scottish Medical Journal 66: 165-165.

   , ,

3. Weinstein JN (2016) Spine 41: 1-2.

   , ,

4. Marshall EC (1989) Assurance of quality vision care in alternative health care delivery systems. J Am Optom Assoc 60: 827-831.

   ,

5. Cutler DM (2021) Building health care better means reining in costs. JAMA Health Forum 2: e210117.

   , ,

6. Lindeque BG (2009) Orthopedics 32: 551.

   , ,

7. Ampomah IG, Malau BS, Aduli AE, Emeto TI (2020) Medicina 56: 271.

   , ,

8. Irwin MR, Opp MR (2017) Neuropsychopharmacology 42: 129-155.

   , ,